VIENNA (dpa-AFX) - Basilea Pharmaceutica AG (BPMUF.PK) announced that it has entered into an agreement with Quintiles (Q) for the commercialization of Zevtera/Mabelio (ceftobiprole medocaril) in Europe. Under the agreement, Quintiles will provide commercial services including a dedicated field force, medical science liaisons, and market access support in selected countries.
Basilea stated that its financial guidance for 2014 remains unchanged, with total operating expenses estimated at CHF 8 to CHF 9 million per month and operating loss estimated at CHF 4 to CHF 5 million per month.
Ceftobiprole (ceftobiprole medocaril, trademarks Zevtera, Mabelio) is a broad-spectrum intravenous cephalosporin antibiotic for the potential empiric treatment of severe bacterial infections where Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens, such as Pseudomonas are suspected. It has gained regulatory authorization from twelve European states for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP) in patients 18 years of age and older, and is currently under regulatory review in Switzerland.
Ronald Scott, Basilea's CEO, said: 'We have made significant progress on national pricing and reimbursement and anticipate launching Zevtera in Germany in the second half of 2014, followed by launches in other key European markets in 2015. In parallel, we continue to assess opportunities for distribution and licensing partnerships in other parts of the world.'
Copyright RTT News/dpa-AFX